The new modern facility will produce rapid tests rapid tests to detect infectious diseases such as Malaria, Dengue and HIV.
The products being produced in the facility will be exported to the countries across the Asia Pacific region.
Featuring 180,000ft² of space, the new facility will initially produce around 150 million rapid diagnostic tests per annum.
Manesar facility has the capacity to double production to more than 300 million tests over time. It currently employs around 300 people.
Alere said the new facility supports the goals of Prime Minister Narendra Modi's Make in India initiative, which seeks to transform India into a global manufacturing hub.
Alere CEO Namal Nawana said: "Alere believes in Prime Minister Modi's vision of 'Make in India,' and is committed to improving access to affordable rapid diagnostics in India and throughout the Asia Pacific region through this new world-class manufacturing facility.
"In particular, the Malaria tests manufactured in Manesar will help support the Government's goal of eradicating this deadly disease in India by 2020."
In February, Abbott signed an agreement to acquire Alere for around $5.8bn.
Once the deal concludes, the combined firm will provide the broadest point of care menu of infectious disease, molecular, cardiometabolic and toxicology testing services.
Based in Waltham of Massachusetts, Alere provides rapid diagnostic tests for cardiometabolic disease, infectious disease and toxicology.
Image: New Manesar facility will produce critical diagnostics for detection of Malaria, Dengue, HIV and other infectious diseases. Photo: courtesy of PRNewsFoto/Alere Inc.
